Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting

2003 ◽  
Vol 45 (2) ◽  
pp. 123-128 ◽  
Author(s):  
L Repetto
2019 ◽  
Vol 156 (1) ◽  
pp. 37-44 ◽  
Author(s):  
A.F. Bouras ◽  
E. Ioos ◽  
A. Aoudia ◽  
H. Kaci ◽  
D. Benaibouche ◽  
...  

2012 ◽  
Vol 22 (1) ◽  
pp. 161-169 ◽  
Author(s):  
Dong Hoon Suh ◽  
Sokbom Kang ◽  
Myong Cheol Lim ◽  
Taek Sang Lee ◽  
Jeong-Yeol Park ◽  
...  

AbstractReflecting the worldwide aging trend and close association of aging with cancer, geriatric oncology is now growing beyond its pioneer years. Nevertheless, geriatric oncology in the gynecologic field is in the beginning stage; indeed, there is no geriatric specialist who is trained in this particular field of gynecologic oncology. Therefore, we held the first workshop in geriatric gynecologic oncology. In this review, we summarize what we discussed at the workshop and provide evidence-based recommendations for the diagnosis and treatment of gynecologic cancer in elderly individuals.


2007 ◽  
Vol 25 (14) ◽  
pp. 1832-1843 ◽  
Author(s):  
Stuart M. Lichtman ◽  
Hans Wildiers ◽  
Etienne Chatelut ◽  
Christopher Steer ◽  
Daniel Budman ◽  
...  

The elderly comprise the majority of patients with cancer and are the recipients of the greatest amount of chemotherapy. Unfortunately, there is a lack of data to make evidence-based decisions with regard to chemotherapy. This is due to the minimal participation of older patients in clinical trials and that trials have not systematically evaluated chemotherapy. This article reviews the available information with regard to chemotherapy and aging provided by a task force of the International Society of Geriatric Oncology (SIOG). Due to the lack of prospective data, the conclusions and recommendations made are a consensus of the participants. Extrapolation of data from younger to older patients is necessary, particularly to those patients older than 80 years, for which data is almost entirely lacking. The classes of drugs reviewed include alkylators, antimetabolites, anthracyclines, taxanes, camptothecins, and epipodophyllotoxins. Clinical trials need to incorporate an analysis of chemotherapy in terms of the pharmacokinetic and pharmacodynamic effects of aging. In addition, data already accumulated need to be reanalyzed by age to aid in the management of the older cancer patient.


Author(s):  
Dorothy Taylor ◽  
Janice Morse ◽  
Andrew Merryweather

Elderly patient falls are expensive and may cause serious harm. Studies have identified the sit-to-stand-and-walk (STSW) task as the task where the greatest number of elderly patient falls occur. There is a great need to identify the particular movement and environmental conditions that lead to these elderly patient falls. This study begins to address this gap by evaluating the elderly patient during self-selected hospital bed egress. Using an observed fall risk episode (FRE) as a fall proxy, statistically significant parameters were identified which include bed height, pausing prior to initiating gait, level of fall risk, and Stand phase. Low bed height was identified as the least safe bed height. Patient-specific bed height (PSBH) using the patient’s lower leg length (LLL) is recommended. In addition, suggested guidelines are presented for clinical application in setting PSBH without measuring the patient’s LLL.


Sign in / Sign up

Export Citation Format

Share Document